If approved, Acadia will sell trofinetide in Europe under license from Neuren. Upon the first commercial sale of the treatment in Europe, Neuren is contracted to receive a US$35 million payment from Acadia. That's in addition to ongoing royalty payments.
How has this led to 10% free fall is beyond me. Smart investors/individuals - please enlighten me here
If approved, Acadia will sell trofinetide in Europe under...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.650B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $13.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.33 | 3716 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |